Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Tislelizumab
How it works
Blocks PD-1, a protein that inhibits the immune system's ability to attack cancer cells, thereby enhancing anti-tumor immune responses.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, tislelizumab improved overall survival in patients with metastatic colorectal cancer, with a median survival of approximately 10.2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Tislelizumab with Chemotherapy and Radiotherapy in Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Treatments for First-Line Squamous Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing LDRT with Immunochemotherapy for Colorectal Cancer with Liver Metastasis | Colorectal Cancer | phase-1 | — | Source → |
| Testing Fruquintinib and Tislelizumab in Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Real-World Study on Lung Cancer Treatment with Tislelizumab | Lung Cancer | preclinical | — | Source → |
| Combination Therapy Shows Promise for Rare Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 55.17% (95% CI, 35.69% - 73.55%). | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Melanoma | phase-1 | — | Source → |
| Testing Tislelizumab in Combination for Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Tislelizumab plus chemotherapy improves survival in advanced lung cancer | Lung Cancer | phase-3 | Median overall survival was 26.1 months in patients who received tislelizumab plus paclitaxel/carboplatin. | Source → |
| Rectal Cancer Trial Testing Chemotherapy, Radiation, and Immunotherapy | Colorectal Cancer | phase-2 | — | Source → |
| Tislelizumab Shows Promise in Lung Cancer Treatment | Lung Cancer | phase-3 | Tislelizumab significantly improved overall survival (hazard ratios: 0.72, 95% CI: 0.63-0.81) and progression-free survival (hazard ratios: 0.61, 95% CI: 0.54-0.68) compared to control treatments. | Source → |
| Cost-effectiveness of tislelizumab plus chemotherapy for lung cancer | Lung Cancer | phase-3 | The addition of tislelizumab to chemotherapy provided an incremental gain of 0.16 QALYs at an additional cost of $7430.73 in China, and 0.28 QALYs at an additional cost of $45,157.35 in the US. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.